A monoclonal antibody is secreted by a single B lymphocyte clone which can only produce a kind of proprietary antibody against an antigen-determining cluster, and has the characteristics of single biological activity and particular specificity of binding with antigen.
The active sites of monoclonal antibody drugs involve a variety of tumor-related signaling pathways and targets. For example, the most common targets are epidermal growth factor receptor (EGFR), vascular endothelial growth factor (VEGF), and epidermal growth factor receptor -2 (her-2 /neu, or egfr-2). Besides, there is a group of targets that are getting a lot of attention called “immune checkpoints”.
After the activation of immune cells that regulate the anti-tumor immune response, a variety of highly expressed receptors on the surface of immune cells bind to the highly expressed ligands on the surface of tumor cells to reduce the strength of the immune response, thus down-regulating the intensity of tumor-related immune response. These immunoregulatory sites are known as immune checkpoints. Currently, the most widely studied immune checkpoints are PD-1, PD-L1, and CTLA-4.
Targetmol provides 30 monoclonal antibody drugs, including the above immune checkpoint inhibitors and other types of targeted antibody inhibitors, for scientific research only.
Cat. No. | 製品名 | CAS No. | Purity | Chemical Structure |
---|---|---|---|---|
T77392 | Pepinemab | 2097151-87-4 | 98% |
Pepinemab
|
Pepinemab(VX 15/2503) is a humanized IgG4 monoclonal antibody targeting sematone 4D. Pepinemab has anti-cancer activity and blocks the activity of SEMA4D, which ... | ||||
T77385 | Idactamab | 2245205-37-0 | 98% |
Idactamab
|
Idactamab (INT-001) is a monoclonal antibody to the human amino acid transport protein ASCT2. | ||||
T77379 | Bexmarilimab | 2259301-27-2 | 98% |
|
Bexmarilimab (FP-1305) is a highly potent humanized anti-CLEVER-1 IgG4 antibody with an IC50 value of 4.51 nM. Bexmarilimab promotes immune conversion of tumor-a... | ||||
T77374 | Ontuxizumab | 946415-62-9 | 98% |
Ontuxizumab
|
Ontuxizumab (MORAb-004) is a monoclonal antibody targeting endomelanic acid with anti-tumor effects.Ontuxizumab is a potent IgG1/κ anti-endothelin (TEM-1 or CD24... | ||||
T77373 | Concizumab | 1312299-39-0 | 98% |
Concizumab
|
Concizumab is an anti-TFPI monoclonal antibody (IgG4 type) that selectively binds to the Kunitz protease inhibitor (KPI) 2 domain of TFPI, thereby blocking the i... | ||||
T77372 | Tisotumab | 1418628-81-5 | 98% |
Tisotumab
|
Tisotumab (Anti-Human F3 Recombinant Antibody) is a human IgG1 monoclonal antibody against tissue factor (TF). Tisotumab is involved in antibody-conjugating drug... | ||||
T77370 | Ianalumab | 1929549-92-7 | 98% |
Ianalumab
|
Ianalumab (VAY-736) is a decarboxylated humanized antibody against BAFF-R. Ianalumab can inhibit the interaction between BAFF and BAFF-R and inhibit the protecti... | ||||
T77369 | Telazorlimab | 2126777-87-3 | 98% |
Telazorlimab
|
Telazorlimab (GBR-830) is a humanized monoclonal antibody that targets the OX40 co-stimulatory receptor on activated T cells. Telazorlimab can be used to treat l... | ||||
T77367 | Urelumab | 934823-49-1 | 98% |
|
Urelumab(BMS-66513) is a humanized IgG4 monoclonal antibody, often used as a CD137 agonist.Urelumab has potential antitumor activity, potentiating tumor cell kil... | ||||
T77364 | Sibeprenlimab | 2382896-07-1 | 98% |
Sibeprenlimab
|
Sibeprenlimab (VIS649) is a humanized IgG 2 monoclonal antibody that suppresses APRIL. Sibeprenlimab has an inhibitory effect on APRIL and may be studied for the... | ||||
T77362 | Vorsetuzumab | 1165740-62-4 | 98% |
Vorsetuzumab
|
Vorsetuzumab (Anti-Human CD70 Recombinant Antibody) is a monoclonal antibody targeting the CD70 antibody. Vorsetuzumab has anticancer activity and can enhance th... | ||||
T77359 | Tezepelumab | 1572943-04-4 | 98% |
Tezepelumab
|
Tezepelumab (AMG 157) is a humanized monoclonal antibody (IgG2λ) targeting TSLP that prevents TSLP from interacting with its heterodimer receptor. Tezepelumab ca... | ||||
T11126 | Durvalumab | 1428935-60-7 | 98% |
|
Durvalumab (MEDI 4736) is a humanized monoclonal antibody targeting PD-L1. It can block the interaction of PD-L1 with PD-1 and CD80, with IC50 values of 0.1 and ... | ||||
T35397 | Sacituzumab | 1796566-95-4 | 98% |
|
Sacituzumab is a humanized IgG1 monoclonal antibody, a naked antibody to Sacituzumab govitecan be used to synthesize antibody-active small-molecule couplings.Sac... | ||||
T77191 | Clivatuzumab | 1622075-09-5 | 98% |
Clivatuzumab
|
Clivatuzumab is a humanized anti-myxinomab, which can target the MUC1 epitope highly expressed on the surface of most pancreatic cancer cells, and has a good the... | ||||
T77170 | Siplizumab | 288392-69-8 | 98% |
Siplizumab
|
Siplizumab (MEDI-507) is a humanized IgG1 monoclonal antibody targeting CD2. Siplizumab selectively depletes effector memory T cells and promotes relative expans... | ||||
T77149 | Cobolimab | 2022215-65-0 | 98% |
Cobolimab
|
Cobolimab (TSR-022) is a potent monoclonal antibody to TIM-3. Cobolimab induces internalization of TIM-3 with an IC50 value of 0.4464 nM. Cobolimab has antitumor... | ||||
T77138 | Ragifilimab | 2207590-51-8 | 98% |
Ragifilimab
|
Ragifilimab (INCAGN-1876) is an agonist monoclonal antibody targeting glucocorticoid-induced TNFR-associated protein (GITR). Ragifilimab can be used in the study... | ||||
T77135 | Tafasitamab | 1422527-84-1 | 98% |
Tafasitamab
|
Tafasitamab (XmAb5574) is an FC-modified humanized monoclonal antibody targeting the human B-cell surface antigen CD19 for the study of diffuse large B-cell lymp... | ||||
T77132 | Clesrovimab | 2429913-18-6 | 98% |
|
Clesrovimab (MK1654) is an anti-respiratory syncytial virus protein F human monoclonal antibody for the prevention and treatment of respiratory syncytial virus i... |